Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

該当なし完了 NCT03696797

対象疾患	Iron, Diabetes, Nonalcoholic Fatty Liver
相	該当なし
スポンサー	Wake Forest University Health Sciences
ステータス	完了
参加者数	132 名
介入（薬剤）	Blood Donation, Sham Blood Donation
開始日	2019年5月3日
完了日	2025年1月3日
結果公開日	2026年6月9日

概要

This is a treatment study to determine if reducing the body's iron stores by blood donation will improve diabetes control and other problems associated with diabetes such as fatty liver disease.

HgbA1c Value

Baseline · percentage of HgbA1c

Treatment Group	6.31 ± 0.75 percentage of HgbA1c
Control Group	6.22 ± 0.57 percentage of HgbA1c

HgbA1c Value

month 6 · percentage of HgbA1c

Treatment Group	6.43 ± 0.77 percentage of HgbA1c
Control Group	6.32 ± 0.56 percentage of HgbA1c

ALT (Alanine Aminotransferase) Value

Baseline · IU/L

Treatment Group	25.5 ± 15.7 IU/L
Control Group	24.1 ± 12.0 IU/L

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский